Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL628 in Early Alzheimer's Disease
NCT07328451Phase 1Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DNL628 in Alzheimer's disease (AD) (2 arms), sponsored by Denali Therapeutics Inc. Primary endpoint: Treatment-Emergent Adverse Events at 37 weeks. Started Jan 2026; status: recruiting.
02
Drugs
DNL628
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07328451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328451.